​

Zevra Therapeutics (ZVRA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Zevra Therapeutics Revenue Highlights

Latest Revenue (Y)

$23.61M

Latest Revenue (Q)

$26.06M

Main Segment (Y)

License

Zevra Therapeutics Revenue by Period

Zevra Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$23.61M-14.02%
2023-12-31$27.46M162.58%
2022-12-31$10.46M-63.50%
2021-12-31$28.65M115.61%
2020-12-31$13.29M3.50%
2019-12-31$12.84M100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31--

Zevra Therapeutics generated $23.61M in revenue during NA 2024, up -14.02% compared to the previous quarter, and up 183.91% compared to the same period a year ago.

Zevra Therapeutics Revenue by Quarter

DateRevenueChange
2025-09-30$26.06M0.70%
2025-06-30$25.88M26.86%
2025-03-31$20.40M69.40%
2024-12-31$12.04M225.93%
2024-09-30$3.69M-16.95%
2024-06-30$4.45M29.90%
2024-03-31$3.42M-74.09%
2023-12-31$13.22M356.55%
2023-09-30$2.90M-65.82%
2023-06-30$8.47M194.20%
2023-03-31$2.88M24.15%
2022-12-31$2.32M-19.31%
2022-09-30$2.87M121.08%
2022-06-30$1.30M-67.21%
2022-03-31$3.96M53.56%
2021-12-31$2.58M31.40%
2021-09-30$1.97M-83.61%
2021-06-30$11.99M-1.08%
2021-03-31$12.12M412.13%
2020-12-31$2.37M22.91%
2020-09-30$1.93M-72.13%
2020-06-30$6.91M230.68%
2020-03-31$2.09M51.82%
2019-12-31$1.38M-88.00%
2019-09-30$11.46M100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31--

Zevra Therapeutics generated $26.06M in revenue during Q3 2025, up 0.70% compared to the previous quarter, and up 585.82% compared to the same period a year ago.

Zevra Therapeutics Revenue Breakdown

Zevra Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23
License$18.00M

Zevra Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 24Mar 24
License$1.30M$1.20M

Zevra Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: License (100.00%).

Zevra Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RIGLRigel Pharmaceuticals$179.28M$69.46M
AKBAAkebia Therapeutics$160.18M$58.77M
PRTAProthena$135.16M$2.42M
GOSSGossamer Bio$114.70M$13.29M
NAGENiagen Bioscience$99.60M$29.13M
RGNXREGENXBIO$83.33M$29.73M
ZVRAZevra Therapeutics$23.61M$26.06M
CRVSCorvus Pharmaceuticals--
VTYXVentyx Biosciences--
KALVKalVista Pharmaceuticals-$13.69M
OLMAOlema Pharmaceuticals--

ZVRA Revenue FAQ

What is Zevra Therapeutics’s yearly revenue?

Zevra Therapeutics's yearly revenue for 2024 was $23.61M, representing a decrease of -14.02% compared to 2023. The company's yearly revenue for 2023 was $27.46M, representing an increase of 162.58% compared to 2022. ZVRA's yearly revenue for 2022 was $10.46M, representing a decrease of -63.50% compared to 2021.

What is Zevra Therapeutics’s quarterly revenue?

Zevra Therapeutics's quarterly revenue for Q3 2025 was $26.06M, a 0.70% increase from the previous quarter (Q2 2025), and a 605.36% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $25.88M, a 26.86% increase from the previous quarter (Q1 2025), and a 481.73% increase year-over-year (Q2 2024). ZVRA's quarterly revenue for Q1 2025 was $20.4M, a 69.40% increase from the previous quarter (Q4 2024), and a 495.65% increase year-over-year (Q1 2024).

What is Zevra Therapeutics’s revenue growth rate?

Zevra Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 125.78%, and for the last 5 years (2020-2024) was 77.69%.

What are Zevra Therapeutics’s revenue streams?

Zevra Therapeutics's revenue streams in c 23 are License

What is Zevra Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Zevra Therapeutics was License. This segment made a revenue of $18M, representing 100.00% of the company's total revenue.